home / stock / virx / virx news


VIRX News and Press, Viracta Therapeutics Inc.

Stock Information

Company Name: Viracta Therapeutics Inc.
Stock Symbol: VIRX
Market: NASDAQ
Website: viracta.com

Menu

VIRX VIRX Quote VIRX Short VIRX News VIRX Articles VIRX Message Board
Get VIRX Alerts

News, Short Squeeze, Breakout and More Instantly...

VIRX - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

2024-06-07 07:22:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out on Friday as we dig into all of the biggest news affecting shares this morning! Moving stocks this morning is heavy trading, drug approval, a ...

VIRX - Viracta Therapeutics Announces New Employment Inducement Grants

SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Mi...

VIRX - Viracta Therapeutics appoints Michael Faerm as CFO

2024-05-14 07:25:19 ET More on Viracta Therapeutics Day One wins FDA nod for brain cancer therapy, Ojemda Viracta slides on lower response rate in trial for lymphoma treatment cohort Read the full article on Seeking Alpha For further details see: Viracta ...

VIRX - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financia...

VIRX - Viracta Therapeutics GAAP EPS of -$0.23

2024-05-09 17:36:13 ET More on Viracta Therapeutics Day One wins FDA nod for brain cancer therapy, Ojemda Viracta slides on lower response rate in trial for lymphoma treatment cohort Seeking Alpha’s Quant Rating on Viracta Therapeutics Historical earni...

VIRX - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Presented positive topline Nana-val results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial in patients with relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV + ) peripheral T-cell lymphoma (PTCL) Initial results from the ongoing NAVAL-1 trial further validate ...

VIRX - Day One wins FDA nod brain cancer therapy, Ojemda

2024-04-23 13:59:37 ET More on Day One Biopharma, Viracta, etc. Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects Viracta slides on lower response rate in trial for lymphoma treatment cohort Xoma to acquire Kinnate Biopharma for $2.3352 -...

VIRX - US Companies Moving the Markets, Evening edition
Wed, Apr 17, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...

VIRX - US Companies Moving the Markets, Evening edition
Mon, Apr 15, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 5.1% to $11.44 on volume of 198,678,404 shares Trio Petroleum Corp. (TPET) rose 22.1% to $0.63 on volume of 179,140,668 shares Soligenix Inc. (SNGX) rose 21.7% to $0.47 on volume of 133,754,026 shares Sup...

VIRX - BSGM, ENLV and WISA among mid-day movers

2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...

Next 10